维普期刊资源整合服务平台（V6.5）

21篇 您的检索式：作者名="Nagrani T"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Correlation be- tween development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase Ⅲ studies 显示文摘	Wacker B Nagrani T Weinberg J	2007	Clin Cancer Res2007，13，13：	1
2	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase Ⅲ studies显示文摘	Wacker B Nagrani T Weinberg J	2007	Clin Cancer Res2007，13，13：	1
3	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies 显示文摘	Wacher B Nagrani T Weinberg J	2007	Clin Cancer Res2007，13，13：	1
4	Correlation between development of rash and efficacy in patients treated with the epider- mal growth factor tyrosine kinase inhibitor erlotinib in two large phase studies 显示文摘	Wackerman B Nagrani T Weinberg J	2007	Clin Cancer Res2007，13，13：	1
5	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase Ⅲ atudios显示文摘	Wacker B Nagrani T Weinherg J		0，，13：	1
6	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase Ⅲ studies显示文摘	Waeker B Nagrani T Weinberg J	2007	Clin Cancer Res2007，13，13：	1
7	Correlation be- tween development of rash and efficacy in patients treated with the epidermal growth factor receptor tyro- sine kinase inhibitor erlotinib in two large phase m studies显示文摘	Wacker B Nagrani T Weinberg J	2007	Clin Cancer Res2007，13，13：	1
8	Correlation between develop- ment of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase studies显示文摘	Wacker B Nagrani T Weinberg J	2007	Clin Cancer Res2007，13，13：	1
9	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase studies显示文摘	Wacker B Nagrani T Weinberg J	2007	Clin Cancer Res2007，13，13：	1
10	Correlation between development of rash and efficacy in patients treatedwith the epidermal growth factor receptor tyrosine kinase inhibitor erlo- tinib in two large phase III studies 显示文摘	WACKER B NAGRANI T WEINBERG J	2007	Clin Cancer Res2007，13，13：	1
11	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase Ⅲ studies显示文摘	Waeker B Nagrani T Weinberg J	2007	Clin Cancer Res2007，13，13：	1
12	Correlation between devel-opment of rash and efficacy in patients treated with the epidermal-growth factor receptor tyrosine kinase inhibitor erlotinib in two large phaseⅢstudies显示文摘	Wacker B Nagrani T Weinberg J etal	2007	Clin Cancer Res2007，13，：	1
13	Correlation between de-velopment of rash and efficacy in patients treated with the epider-mal growth factor receptor tyrosine kinase inhibitor erlotinib in twolarge phase III studies 显示文摘	Wacker B Nagrani T Weinberg J	2007	Clin Cancer Res2007，13，13：	1
14	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase Ⅲ studies显示文摘	Wacker B Nagrani T Weinberg J	2007	Clin Cancer Res2007，13，13：	1
15	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase Ⅲ studies显示文摘	Wacker B Nagrani T Weinberg J	2007	Clin Cancer Res2007，13，13：	1
16	Correlation between development of rash and efficacy in patients treated with the epidermal growth\sfactor receptor tyrosine kinase inhinbitor erlotinib in two large phaseⅢstudies显示文摘	Wacker B Nagrani T Weinberg J	2007	Clin Cancer Res2007，14，13：	1
17	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor receptor tyrosine kinase inhibitor erlo-tinib in two large phase Ⅲ studies显示文摘	Wacker B Nagrani T Weiberg J		0，，13：	1
18	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies显示文摘	Wacker B Nagrani T Weinberg J	2007	Clin Cancer Res2007，13，13：	1
19	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase I11 studies显示文摘	Wacker B Nagrani T Weinberg J	2007	Clin Cancer Res2007，13，13：	1
20	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase Ⅲ studies显示文摘	Wacker B Nagrani T Weinberg J	2007	Clin Cancer Res2007，13，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示